Alain Huriez
Oprichter bij Luxfold S.A.
Oorsprong van het eerstegraads netwerk van Alain Huriez
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.
30
| Private Company | Investment Managers | 30 |
Tc Land Expression SA
 Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
AdBio Partners SAS
 AdBio Partners SAS Investment ManagersFinance AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France.
6
| Holding Company | Investment Managers | 6 |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Augustine Therapeutics NV
 Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.
6
| Holding Company | Medical/Nursing Services | 6 |
DiogenX SAS
 DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.
4
| Holding Company | Biotechnology | 4 |
Urania Therapeutics SAS
 Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France.
3
| Holding Company | Biotechnology | 3 |
Luxfold S.A.
 Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg.
2
| Private Company | Biotechnology | 2 |
Alderaan Biotechnology SAS
 Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France.
2
| Holding Company | Biotechnology | 2 |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Alain Huriez via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | Chairman Director/Board Member | |
Ubiquisys Ltd.
 Ubiquisys Ltd. Computer CommunicationsElectronic Technology Ubiquisys Ltd. provides communication services. The company was founded on October 1, 2004 and is headquartered in Cardiff, the United Kingdom. | Computer Communications | Director/Board Member Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director/Board Member Chairman | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin | |
| University of Oxford | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree Doctorate Degree Undergraduate Degree | |
| University of Aberdeen | College/University | Doctorate Degree Undergraduate Degree | |
Wellcome Trust Technology Transfer
 Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Investment Managers | Private Equity Analyst Private Equity Analyst | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal | |
| University of Strathclyde | College/University | Undergraduate Degree | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
| University College London | College/University | Undergraduate Degree Doctorate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree | |
| ESSEC Business School | College/University | Corporate Officer/Principal Undergraduate Degree | |
| ESIEE | College/University | Graduate Degree | |
Axonics Women's Health Ltd.
 Axonics Women's Health Ltd. Pharmaceuticals: MajorHealth Technology Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder | |
NovAliX SAS
 NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Biotechnology | Chief Executive Officer Founder | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Hemarina SA
 Hemarina SA BiotechnologyHealth Technology Hemarina SA operates as a biotechnology company which develops oxygen carrier for therapeutic and industrial applications. It offers organ preservation, wound healing, hemoglobin oxygen-carrier, cell culture and bioproduction and other perspective products. The company was founded by Franck Zal, Elisabeth Leize, Morgane Rousselot and Laurent Meijer on March 26, 2007 and is headquartered in Morlaix, France. | Biotechnology | Director/Board Member | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| SENSORION | Pharmaceuticals: Major | Director/Board Member | |
Nicoventures Trading Ltd.
 Nicoventures Trading Ltd. Industrial ConglomeratesProducer Manufacturing Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom. | Industrial Conglomerates | Chairman Director/Board Member | |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Analyst Corporate Officer/Principal | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Director/Board Member | |
Capital Grand Est SAS
 Capital Grand Est SAS Investment ManagersFinance Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France. | Investment Managers | Private Equity Analyst | |
Bioaxial SAS
 Bioaxial SAS Electronic ComponentsElectronic Technology Bioaxial SAS develops and supplies live cell imaging instruments. It develops, manufactures and markets a super-resolution instrument for the life sciences and medical research communities. The firm's products include add-on module CODIM100 and Stand-Alone. The company was founded by Louis-Philippe Braitbart and Gabriel Sirat on February 24, 2010 and is headquartered in Paris, France. | Electronic Components | Director/Board Member | |
Inoviem Scientific SAS
 Inoviem Scientific SAS BiotechnologyHealth Technology Inoviem Scientific SAS offers preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Its services include preclinical and drug discovery, patient stratification and biomarkers clinical development. The company was founded by Pierre Eftekhari in 2011 and is headquartered in Strasbourg, France. | Biotechnology | Director/Board Member | |
| OSE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer | |
BiovelocITA Srl
 BiovelocITA Srl Investment ManagersFinance Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy. | Investment Managers | Private Equity Investor | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder Chairman Founder | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member Founder Chief Executive Officer | |
Yukin Therapeutics SAS
 Yukin Therapeutics SAS Pharmaceuticals: MajorHealth Technology Yukin Therapeutics SAS manufactures pharmaceutical preparations. The company was founded by Matthieu Coutet on June 29, 2018 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Chief Executive Officer | |
Felix Management I Ltd.
 Felix Management I Ltd. Investment ManagersFinance Part of Felix Capital Partners LLP, Felix Management I Ltd. provides fund management services. The company is based in Edinburgh, UK. Founded in 2015. | Investment Managers | Director/Board Member Director/Board Member | |
Axilum Robotics SAS
 Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
| Verenigd Koninkrijk | 18 |
| Frankrijk | 14 |
| Verenigde Staten | 13 |
| België | 5 |
| Nederland | 3 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 10 |
| Finance | 7 |
| Commercial Services | 5 |
| Electronic Technology | 3 |
Operationeel
| Director/Board Member | 258 |
| Corporate Officer/Principal | 100 |
| Chairman | 59 |
| Chief Executive Officer | 46 |
| Founder | 43 |
Sterkste connecties
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Marc M. P. de Garidel | 31 |
| Mohammed Malik | 24 |
| Frédéric Court | 23 |
| Dale Pfost | 22 |
| Fiona MacLaughlin | 22 |
| Ian James Nicholson | 20 |
| Alan Walts | 17 |
| Klaus Breiner | 16 |
| Maryvonne Hiance | 15 |
| Katrine Bosley | 15 |
| Donald Lee Drakeman | 13 |
| Matthieu Coutet | 13 |
| Erik van den Berg | 13 |
| Satish Jindal | 13 |
- Beurs
- Insiders
- Alain Huriez
- Bedrijfsconnecties
